期刊
MEDICINAL RESEARCH REVIEWS
卷 28, 期 6, 页码 929-953出版社
WILEY
DOI: 10.1002/med.20128
关键词
antivirals; valaciclovir; BVDU; DHPA; cidofovir; adefovir; tenofovir; stavudine; HEPT; TIBO; AMD3100
This review article, while autobiographical to some extent, describes the discovery often (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with virus infections: (i) valaciclovir, (ii) BVDU, (iii) DHPA, (iv) cidofovir, (v) adefovir, (vi) tenofovir, (vii) stavudine, (viii) HEPT, (ix) TIBO, and (x) AMD3100. Successful drug development, as is certainly true for antiviral drugs and exemplified for the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir, requires patience and perseverance, and a close continuous and dedicated interaction between Chemistry, Biology/Medicine and Industry. (C) 2008 Wiley Periodicals, Inc. Med Res Rev, 28, No. 6, 929-953, 2008
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据